News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novavax, Inc. (NVAX) - Product Pipeline Review - 2014


6/10/2014 10:37:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON
, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Novavax, Inc. - Product Pipeline Review - 2014

http://www.reportbuyer.com/pharma_healthcare/therapeutic/novavax_inc_product_pipeline_review_2013.html

Novavax, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Novavax, Inc. - Product Pipeline Review - 2014', provides an overview of the Novavax, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novavax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Novavax, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Novavax, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Novavax, Inc.'s pipeline products

Reasons to buy

- Evaluate Novavax, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Novavax, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Novavax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Novavax, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novavax, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Novavax, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents

Novavax, Inc. Snapshot 5
Novavax, Inc. Overview 5
Key Information 5
Key Facts 5
Novavax, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Novavax, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Novavax, Inc. - Pipeline Products Glance 14
Novavax, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Novavax, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Novavax, Inc. - Drug Profiles 18
H1N1-2009 VLP Vaccine 18
Product Description 18
Mechanism of Action 18

R&D Progress 18
Quadrivalent Seasonal Influenza Virus-Like Particle Vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Respiratory Syncytial Virus Vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Trivalent Seasonal Influenza VLP Vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
H5N1 VLP Influenza Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
H7N9 VLP Influenza Vaccine 27
Product Description 27

Mechanism of Action 27
R&D Progress 27
E-Selectin Tolerogen 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MERS-CoV Vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Respiratory Syncytical Virus Fusion + Seasonal Influenza Virus-Like Particle 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SARS-CoV Vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Vaccine For Rabies 33

Product Description 33
Mechanism of Action 33
R&D Progress 33
Varicella Zoster Virus Vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Novavax, Inc. - Pipeline Analysis 35
Novavax, Inc. - Pipeline Products by Target 35
Novavax, Inc. - Pipeline Products by Route of Administration 36
Novavax, Inc. - Pipeline Products by Molecule Type 37
Novavax, Inc. - Recent Pipeline Updates 38
Novavax, Inc. - Dormant Projects 48
Novavax, Inc. - Company Statement 49
Novavax, Inc. - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables

Novavax, Inc., Key Information 5
Novavax, Inc., Key Facts 5
Novavax, Inc. - Pipeline by Indication, 2014 8
Novavax, Inc. - Pipeline by Stage of Development, 2014 9
Novavax, Inc. - Monotherapy Products in Pipeline, 2014 10
Novavax, Inc. - Combination Treatment Modalities in Pipeline, 2014 11
Novavax, Inc. - Partnered Products in Pipeline, 2014 12
Novavax, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13
Novavax, Inc. - Phase II, 2014 14
Novavax, Inc. - Phase I, 2014 15
Novavax, Inc. - Preclinical, 2014 16
Novavax, Inc. - Discovery, 2014 17
Novavax, Inc. - Pipeline by Target, 2014 35
Novavax, Inc. - Pipeline by Route of Administration, 2014 36
Novavax, Inc. - Pipeline by Molecule Type, 2014 37
Novavax, Inc. - Recent Pipeline Updates, 2014 38
Novavax, Inc. - Dormant Developmental Projects,2014 48
Novavax, Inc., Other Locations 56
Novavax, Inc., Subsidiaries 56

List of Figures

Novavax, Inc. - Pipeline by Top 10 Indication, 2014 7
Novavax, Inc. - Pipeline by Stage of Development, 2014 9
Novavax, Inc. - Monotherapy Products in Pipeline, 2014 10
Novavax, Inc. - Partnered Products in Pipeline, 2014 12
Novavax, Inc. - Pipeline by Top 10 Target, 2014 35
Novavax, Inc. - Pipeline by Top 10 Route of Administration, 2014 36
Novavax, Inc. - Pipeline by Top 10 Molecule Type, 2014 37

Read the full report:
Novavax, Inc. - Product Pipeline Review - 2014

http://www.reportbuyer.com/pharma_healthcare/therapeutic/novavax_inc_product_pipeline_review_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer



Help employers find you! Check out all the jobs and post your resume.
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES